Answers are grounded in this paper and cite their sources.
Glycosylation alterations have emerged as significant indicators in the landscape of cancer diagnosis, with aberrant N-glycans standing out as potential biomarkers. The existing methods for purifying N-glycans mainly rely on their hydrophilicity, affinity, and size. These methods exhibit relatively weak binding forces and low specificity based on non-covalent interactions. Moreover, the current liquid chromatography-based N-glycan purification and detection techniques must be bettered for clinical settings' rapid diagnostic requirements. Here, we have developed a method involving the covalent binding of graphene modified with photocleavable amino groups to N-glycans in hepatocellular carcinoma (HCC) patients' serum glycoproteins. The N-glycans are identified using MALDI-TOF/TOF MS, catering to the requirements of biological research and the diagnosis of liver cancer disease. Specifically, amino-functionalized graphene is linked with photocleavable groups bearing hydrazide functional group, then undergoes acyl hydrazone covalent reaction with aldehyde groups on the side chains of oxidized monosaccharides to capture the N-glycans. Finally, under UV irradiation at a wavelength of 356 nm for 15 s, the ortho-nitrobenzyl photocleavable groups undergo cleavage, completing the release of captured N-glycans, which are then subjected to MALDI-TOF/TOF MS mass spectrometry for detection. Our findings demonstrate significant differences in the N-glycan profiles between serum samples of liver cancer patients and healthy individuals. These differences are characterized by increased abundance and molecular weight of N-glycans. Through biomarker screening, one N-glycan with an m/z ratio of 1847.01 shows the potential to serve as a diagnostic biomarker for liver cancer (P < 0.05). Our research underscores the potential of photocleavable amino-modified graphene for detecting aberrant N-glycans in HCC patients' serum to elucidate the intricate between aberrant N-glycan alterations and HCC. This research paves the way for developing novel biomarkers, diagnostic strategies, and therapeutic interventions to combat this complex disease.
No takes yet. Share an insight, caveat, or question.
Chao et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: